TY - JOUR T1 - A Phase II Study Repurposing Atomoxetine for Neuroprotection in Mild Cognitive Impairment JF - medRxiv DO - 10.1101/2021.07.06.21260104 SP - 2021.07.06.21260104 AU - Allan I. Levey AU - Deqiang Qiu AU - Liping Zhao AU - William T. Hu AU - Duc M. Duong AU - Lenora Higginbotham AU - Eric B. Dammer AU - Nicholas T. Seyfried AU - Thomas S. Wingo AU - Chadwick M. Hales AU - Malú Gámez Tansey AU - David Goldstein AU - Anees Abrol AU - Vince D. Calhoun AU - Felicia C. Goldstein AU - Ihab Hajjar AU - Anne M. Fagan AU - Doug Galasko AU - Steven D. Edland AU - John Hanfelt AU - James J. Lah AU - David Weinshenker Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/08/2021.07.06.21260104.abstract N2 - The locus coeruleus (LC) is the initial site of Alzheimer’s disease neuropathology, with hyperphosphorylated Tau appearing in early adulthood followed by neurodegeneration in dementia. LC dysfunction contributes to Alzheimer’s pathobiology in experimental models, which can be rescued by increasing norepinephrine (NE) transmission. To test NE augmentation as a potential disease-modifying therapy, we performed a biomarker-driven phase II trial of atomoxetine, a clinically-approved NE transporter inhibitor, in subjects with mild cognitive impairment due to Alzheimer’s disease.The design was a single-center, 12-month double-blind crossover trial. Thirty-nine participants with mild cognitive impairment (MCI) and biomarker evidence of Alzheimer’s disease were randomized to atomoxetine or placebo treatment. Assessments were collected at baseline, 6- (crossover) and 12-months (completer). Target engagement was assessed by CSF and plasma measures of NE and metabolites. Prespecified primary outcomes were CSF levels of IL1α and Thymus-Expressed Chemokine. Secondary/exploratory outcomes included clinical measures, CSF analyses of Aβ42, Tau, and pTau181, mass spectrometry proteomics, and immune-based targeted inflammation-related cytokines, as well as brain imaging with MRI and FDG-PET.Baseline demographic and clinical measures were similar across trial arms. Dropout rates were 5.1% for atomoxetine and 2.7% for placebo, with no significant differences in adverse events. Atomoxetine robustly increased plasma and CSF NE levels. IL-1α and Thymus-Expressed Chemokine were not measurable in most samples. There were no significant treatment effects on cognition and clinical outcomes, as expected given the short trial duration. Atomoxetine was associated with a significant reduction in CSF Tau and pTau181 compared to placebo, but not associated with change in Aβ42. Atomoxetine treatment also significantly altered CSF abundances of protein panels linked to brain pathophysiologies, including synaptic, metabolism, and glial immunity, as well as inflammation-related CDCP1, CD244, TWEAK, and OPG proteins. Treatment was also associated with significantly increased BDNF and reduced triglycerides in plasma. Resting state fMRI showed significantly increased inter-network connectivity due to atomoxetine between the insula and the hippocampus. FDG-PET showed atomoxetine-associated increased uptake in hippocampus, parahippocampal gyrus, middle temporal pole, inferior temporal gyrus, and fusiform gyrus, with carry-over effects six months after treatment.In summary, atomoxetine treatment was safe, well tolerated, and achieved target engagement in prodromal Alzheimer’s disease. Atomoxetine significantly reduced CSF Tau and pTau, normalized CSF protein biomarker panels linked to synaptic function, brain metabolism, and glial immunity, and increased brain activity and metabolism in key temporal lobe circuits. Further study of atomoxetine is warranted for repurposing the drug to slow Alzheimer’s disease progression.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01522404Funding StatementFunding for the study was provided by the Cox and Kenan Family foundations, and the Alzheimers Drug Discovery Foundation. The research reported here was also supported (in part) by the Division of Intramural Research, NIH, NINDS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was registered with ClinicalTrial.gov (NCT01522404) after the protocol and informed consent form were reviewed and approved by the Emory Institutional Review Board (IRB) committee (IRB00054397).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrial.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request.AbbreviationsAβamyloid-betaADAS-CogAlzheimer’s Disease Assessment Scale-Cognitive SubscaleADDFAlzheimer Drug Discovery FoundationADNIAlzheimer’s disease neuroimaging initiativeBDNFbrain-derived neurotrophic factorCSFcerebrospinal fluidDHPG3,4-dihydroxyphenylglycolDREADDdesigner receptors exclusively activated by designer drugsDSMBData and Safety Monitoring BoardFDGfluorodeoxyglucoseGDSGeriatric Depression ScaleLClocus coeruleusL-DOPSL-3,4-dihydroxyphenylserineLMLogical MemoryMCImild cognitive impairmentMMSEMini Mental Status ExamMSmass spectrometryNEnorepinephrineNETnorepinephrine transporterTECKThymus Expressed ChemokineTMTtandem mass tagging ER -